-11642

Patent Docket P1093P1D1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Manuel Baca et al.

Serial No.: 09/723,752

Filed: November 27, 2000

For:

ANTI-VEGF ANTIBODIES

Group Art Unit: 1642 /

Examiner: Helms, Larry Ronald

Confirmation No: 6340

CUSTOMER NO: 09157

### CERTIFICATE OF MAILING

NON OF CENTER 1000 SONS I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30 2003

Tom Marrs

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

#### 37 CFR §1.97(b) $\Pi$

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§ 1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

### . 37 CFR §1.97(c) $\prod$

by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the

Page 2

mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

# [X] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [X] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement/ was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [X] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. <u>08/908,469</u>, filed <u>August 6, 1997</u> and relied upon in this application for an earlier filing date under 35 USC §120.

Serial No.: 09/723,752

Filed: November 27, 2000

Page 3

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: October 20, 2003

Sfeven X. Cui

Reg. No. 44,637 Telephone No. (650)225-8674

		/	ITE							
		/0	IN 0 3 2003 PE				Sh	neet <u>1</u>	of <u>1</u>	
FORM	PTO-	1449 N	M O 3 DE	U.S. Dept. of Commerce Atty		Docket No.		Serial No.		
				Patent and Trademark Office	P1093		0.9	09/723752		
		<b>₹</b>	WA TRADEMA	Patent and Trademark Onice	Applic	ant				
LIST	OF DI	SCLOSURES CITED B	PAPPEICANT		Baca	et al.				
(Use several sheets if necessary)					Filing [	Filing Date		Group		
						Nov 2000	ov 2000 164			
				U.S. PATENT DOCUMENTS	*					
Examiner nitials	•	Document Number	Date	Name		Class	Subclass	oclass Filing Date		
	79	2002/032315	14.03.02	Baca et al.						
	80	6,037,454	14.03.00	Jardieu et al.						
		-	•	FOREIGN PATENT DOCUMENTS	S		•			
xaminer nitials		Document Number	Date	Country		Class	Subclass	Transl Yes	ation No	
	81	WO 98/45331	15.10.98	PCT					<u> </u>	
	82	WO 98/45332	15.10.98	PCT				•		
			OTHER DISCL	OSURES (Including Author, Title, Date,	Pertinen	t Pages, etc.	.)			
	83			an Anti-Vascular Endothelial Gr er Disorders" <u>Cancer Research</u> 57					r the	
		· .	·							
		!								

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Date Considered